Company profile: DelSiTech
1.1 - Company Overview
Company description
- Provider of biodegradable silica-based controlled-release drug delivery technologies and drug development services, focusing on parenteral and local administration. Offers Silica Matrix platform for small molecules, biopharmaceuticals, and viral vectors; long-acting injectables, ocular drug delivery, and supergeneric/505(b)(2) products such as DST1308 and DST2105.
Products and services
- Long-Acting Injectables: Parenteral-focused depots built with Silica Matrix that achieve sustained drug release across diverse therapeutic areas for long-acting treatment profiles
- DelSiTech Silica Matrix: A biodegradable silica-based controlled-release platform that encapsulates small molecules, biopharmaceuticals, and viral vectors, enabling sustained parenteral and local administration of drug products
- Supergeneric/505(b)(2) Drug Development: Programs that integrate Silica Matrix with known active substances to produce supergeneric products exhibiting superior characteristics versus original brands under the 505(b)(2) pathway
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to DelSiTech
Cytovale
HQ: United States
Website
- Description: Provider of early detection diagnostic technologies for immune-mediated diseases, including the IntelliSep Test for rapid sepsis identification with results in under 10 minutes to aid emergency department triage, powered by microfluidics, precision imaging, and machine learning to analyze complex biological data and perform detailed cellular analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytovale company profile →
Genelabs Technologies
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on discovering and developing therapies for infectious diseases, offering drug discovery services and medications including Morphine for severe pain, Atomoxetine (Strattera) for ADHD, Finasteride (Propecia) for male pattern hair loss, and Valacyclovir (Valtrex) for herpes and shingles.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genelabs Technologies company profile →
Iterum Therapeutics
HQ: Ireland
Website
- Description: Provider of clinical-stage anti-infectives targeting multi-drug resistant pathogens. Offers sulopenem, an oral and IV penem antibiotic with broad-spectrum activity against multi-drug resistant gram-negative infections in hospital and community settings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iterum Therapeutics company profile →
Abivax
HQ: France
Website
- Description: Provider of clinical-stage biotechnology therapies that mobilize the body's natural immune machinery to treat autoimmune diseases, viral infections, and cancer, including obefazimod for ulcerative colitis (Phase 3), planned Phase 2b for Crohn's disease, exploration as combination therapy for ulcerative colitis in preclinical studies, and nonclinical evaluation for additional chronic inflammatory indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abivax company profile →
Bugworks Research
HQ: India
Website
- Description: Provider of drug discovery focused on combating antimicrobial resistance (AMR) and small molecule cancer therapeutics, including BWC2094 targeting the adenosine pathway (CRC, NSCLC, TNBC, pancreas, prostate, RCC, HNSCC); ATM/DNA-PK dual inhibitors (BWC5036/BWC5089); BWC5044/BWC5077, BWC4496; spliceosome modulators/DNA damage agents; and ADC payload opportunities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bugworks Research company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for DelSiTech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to DelSiTech
2.2 - Growth funds investing in similar companies to DelSiTech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for DelSiTech
4.2 - Public trading comparable groups for DelSiTech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →